NICE changes mind and backs new drug for severe asthma | Nursing Times
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison - Journal of Allergy and Clinical Immunology
Injectable asthma drug reslizumab approved by European Commission - The Pharmaceutical Journal
BUY Reslizumab (CINQAIR) 10 mg/mL Teva Respiratory, LLC
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Brand name: Auvi-Q
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
New Severe Asthma Rx Gets Green Light | RxWiki
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice - CHEST
CINQAIR® (reslizumab) Injection – About Asthma Control
cinqaero - Twitter Search / Twitter
Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation - Respiratory Medicine
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials - The Journal of Allergy and Clinical Immunology: In Practice
Reslizumab | New Drug Approvals
Reslizumab – All About Drugs
Israeli Pharma gets FDA Approval for Asthma Antibody
Reslizumab
Teva files MAA for asthma treatment reslizumab
A Guide to the Prescription and Service Request Form
A Guide to the PRESCRIPTION AND SERVICE REQUEST FORM FOR CINQAIR® ( reslizumab) Injection
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
Upcoming Reslizumab PDUFA- Approval Odds, And What It Means For Teva (NYSE: TEVA) | Seeking Alpha
